Disc Medicine (IRON) Free Cash Flow (2020 - 2026)
Disc Medicine (IRON) reported Free Cash Flow of -$62.2 million for Q1 2026, down 47.38% year-over-year from -$118.3 million in Q1 2025, and down 43.67% quarter-over-quarter from -$43.3 million in Q4 2025.
Disc Medicine (IRON) Free Cash Flow (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Free Cash Flow data on file, last reported at -$62.2 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$62.2 million, down 47.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$201.3 million (down 95.49% YoY), and the FY2025 annual result was -$181.3 million, down 92.02% from the prior year.
- Free Cash Flow declined to -$62.2 million in Q1 2026 per IRON's latest filing, from -$43.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$7.5 million in Q3 2023 and troughed at -$62.2 million in Q1 2026.
- A 5-year average of -$26.7 million and a median of -$17.8 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow soared 42.15% in 2022, then plunged 211.59% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$9.7 million in 2022, then sank by 83.93% to -$17.8 million in 2023, then sank by 57.44% to -$28.0 million in 2024, then sank by 54.59% to -$43.3 million in 2025, then slumped by 43.67% to -$62.2 million in 2026.
- Business Quant data shows IRON's Free Cash Flow at -$62.2 million in Q1 2026, -$43.3 million in Q4 2025, and -$47.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Disc Medicine | 2.73 Bn | 2.00 Bn | - | -62.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.24 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Dec 31, 2025 | -43.32 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Sep 30, 2025 | -47.83 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Jun 30, 2025 | -47.95 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Mar 31, 2025 | -42.23 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Dec 31, 2024 | -28.02 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Sep 30, 2024 | -17.35 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Mar 31, 2024 | -33.67 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Dec 31, 2023 | -17.80 Mn |